We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sinclair Pha | LSE:SPH | London | Ordinary Share | GB0033856740 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.80 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSPH
RNS Number : 1138U
Sinclair Pharma PLC
19 October 2017
Sinclair Pharma plc
New CE mark granted for Silhouette Soft(R)
London, 19 October 2017 Sinclair Pharma plc (SPH.L), ("Sinclair") the international aesthetics company, is pleased to announce that Silhouette Soft(R) has been re-issued a European CE mark, effective immediately.
As previously disclosed by Sinclair, the de-designation of a number of European Notified Bodies affected the registrations of numerous medical devices across the industry, including Silhouette Soft(R). The dossier for Silhouette Soft(R) has been reviewed and relevant audits completed to the satisfaction of the Group's new Notified Body. The CE mark renewal process did not affect supply of Silhouette Soft(R) and sales under the new CE mark can commence immediately.
For further information please contact:
Hot Features
Premium
Sinclair Pharma plc Tel: +44 (0) 20 7467
6920
Chris Spooner
Alan Olby
Andy Crane
Peel Hunt LLP (NOMAD and Tel: +44 (0) 20 7418
Joint Broker) 8900
James Steel
Oliver Jackson
RBC Capital Markets (Joint Tel: +44 (0) 20 7653
Broker) 4000
Marcus Jackson
Laura White
Media enquiries
FTI Consulting Tel: +44 (0) 203 727
1000
Ben Atwell
Brett Pollard
Stephanie Cuthbert
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.
For more information, please visit
www.sinclairpharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGGGWPUUPMGWB
(END) Dow Jones Newswires
October 19, 2017 09:25 ET (13:25 GMT)
1 Year Sinclair Pharma Chart |
1 Month Sinclair Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
